ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems (Q38334927)

2 September 2017

1 reference

title

ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems (English)

1 reference

2 September 2017

0 references

Linda Härmark

1

1 reference

2 September 2017

Florence van Hunsel

series ordinal

2

1 reference

2 September 2017

Birgitta Grundmark

series ordinal

3

1 reference

2 September 2017

1 April 2015

1 reference

2 September 2017

1 reference

2 September 2017

38

1 reference

2 September 2017

337-347

1 reference

2 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-015-0264-1

2 September 2017

0 references

cites work

Evaluation of FDA safety-related drug label changes in 2010.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Experiences with adverse drug reaction reporting by patients: an 11-country survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Consumer adverse drug reaction reporting: a new step in pharmacovigilance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Adverse drug reaction reporting by patients: an overview of fifty countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Under-reporting of adverse drug reactions : a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

What motivates patients to report an adverse drug reaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Motives for reporting adverse drug reactions by patient-reporters in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

"Serious" and "severe" adverse drug reactions need defining

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Adverse drug reaction reporting by patients in the Netherlands: three years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Adverse drug reaction reports of patients and healthcare professionals-differences in reported information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Consumers of natural health products: natural-born pharmacovigilantes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Medicine safety: experiences and perceptions of the general public in Liverpool

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

What can we learn from parents about enhancing participation in pharmacovigilance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

A Pill for the Ill? Patients' Reports of Their Experience of the Medical Encounter in the Treatment of Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Low awareness of adverse drug reaction reporting systems: a consumer survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Sexual dysfunction, depression, and the impact of antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Digital drug safety surveillance: monitoring pharmaceutical products in twitter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0264-1

Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors.

21 January 2018

1 reference

12 December 2020

Does sexual dysfunction persist upon discontinuation of selective serotonin reuptake inhibitors?

1 reference

12 December 2020

[Direct reporting of side effects by the patient: favourable experience in the first year]

1 reference

12 December 2020

[Thrombosis and embolism during Diane-35 use: analysis of reports made to the Netherlands Pharmacovigilance Centre Lareb]

1 reference

12 December 2020

The Erice Manifesto: for global reform of the safety of medicines in patient care

1 reference

12 December 2020

Reflections after the Diane affair

1 reference

12 December 2020

[Reporting of side-effects--a system in need of improvement. Reporting of a physician questionnaire]

1 reference

12 December 2020

Important information regarding reporting of adverse drug reactions: a qualitative study

1 reference

12 December 2020

Serotonin reuptake inhibitors and shocklike paresthesia

1 reference

12 December 2020

Direct reporting by patients of adverse drug reactions in Spain

1 reference

12 December 2020

Temporal relationship between multiple drugs and multiple events in patient reports on adverse drug reactions: findings in a pilot study in Japan

1 reference

12 December 2020

Drug safety: reporting systems for the general public

1 reference

12 December 2020

10.1007/S40264-015-0264-1

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

0 references

1 reference